Fig. 2From: Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trialsMedian absolute change from baseline to week 52 across all assessed PROs in nintedanib-treated patients, by a) GAP stage, b) % predicted FVC, c) % predicted DLCO, d) CPI and e) SGRQ total score (analysis 3)Back to article page